BenjaminWalkerFischer-ValuckMDMS

PubMed

• Does Chemo-Radiotherapy Improve Survival Outcomes vs. Radiotherapy Alone for High-Grade cT1 Urothelial Carcinoma of the Bladder?
  Neal Andruska, Michael R Waters, Benjamin W Fischer-Valuck, Zachary L Smith, Eric H Kim
  Clinical Genitourinary Cancer. 2023-12-01
• 2 citations
  Radiation Facility Volume and Survival for Men With Very High-Risk Prostate Cancer Treated with Radiation and Androgen Deprivation Therapy.
  Nikhil Sebastian, Subir Goyal, Yuan Liu, James R Janopaul-Naylor, Pretesh R Patel
  JAMA Network Open. 2023-08-01
• 3 citations
  Bladder only versus bladder plus pelvic lymph node chemoradiation for muscle-invasive bladder cancer.
  Sagar A Patel, Yuan Liu, Abhishek A Solanki, Brian C Baumann, Jason A Efstathiou
  Urologic Oncology. 2023-07-01

Journal Articles

• Prognostic utility of serial PET/CT imaging following stereotactic body radiation therapy (SBRT) in early stage lung cancer: a single institution experience  
  Fischer-Valuck BW, Rosen LR, Katz S, Durci M, Wu T, Journal of Radiation Oncology, 9/2014
• Influence of patient characteristics on survival following treatment with helical stereotactic body radiotherapy (SBRT) in stage I non-small-cell lung cancer  
  Fischer-Valuck BW, Durci M, Katz S, Wu T, Syh J, Syh J, Patel B, Rosen L, Thoracic Cancer, 2/4/2013

Books/Book Chapters

• Cellular Solutions for Clinical Challenges 
  Chapter: Regulating in Vitro Motility of Human Mesenchymal Stem Cells with Macrophage Migration Inhibitory Factor (MIF) and a Small-Molecule MIF Antagonist. 
  Page 149 - 160O’Connor KC, Barrilleaux BL, Phinney DG, Fischer-Valuck BW, Russell KC, Prockop DJSpringer, Dordrecht, Netherlands2012

Lectures

• Impact of facility patient volume on overall survival in patients with muscle invasive bladder cancer undergoing trimodality bladder preservation therapy. 
  2019 ASCO Annual Meeting - 6/1/2019